Edison Expands European Biotech Presence
News Jan 18, 2012
Edison has published a comprehensive report examining the investment merits of Transgene, focusing on the potential of its four lead immunotherapy products for various cancers and infectious diseases, including hepatitis C. The report is timely because of the increased interest in immunotherapies to treat cancers after the approvals of Dendreon’s Provenge and Bristol-Myers Squibb’s Yervoy, and activity in the hepatitis C field following recent acquisitions by Roche, Gilead and Bristol-Myers Squibb.
The launch of coverage on Transgene is part of a programme of research initiations on biotech companies worldwide. Edison covers over 65 biotech companies in Europe, North America and Australia. Its biotech research team has a particular focus on companies active in the area of oncology with 15 companies now under active coverage.
Edison has pioneered a scientific detail-oriented approach to analysing companies in the biotech sector that aims to inform investors while providing a realistic assessment of the competitive strengths and threats to key drug development programmes. All facts are carefully sourced and the analysis is underpinned by rigorous financial models. Edison’s reports provide an overall company valuation without any specific stock recommendation or target price.
Scientists working in a range of disciplines joined forces to identify a new approach to combat African sleeping sickness. Their research revealed a promising strategy to develop a suitable agent. This novel concept could also be employed in the future rational design of drugs for the treatment of other diseases.READ MORE
A new study has identified a drug that potentially could make a common type of immunotherapy for cancer even more effective. The study in laboratory mice found that the drug dasatinib, which is FDA-approved to treat certain types of leukemia, greatly enhances responses to a form of immunotherapy that is used against a wide range of other cancers.